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Abstract
Background: Prostate cancer is the most common cancer in men in the UK. NICE guidelines on recognition and
referral of suspected cancer, recommend performing digital rectal examination (DRE) on patients with urinary
symptoms and urgently referring if the prostate feels malignant. However, this is based on the results of one case
control study, so it is not known if DRE performed in primary care is an accurate method of detecting prostate cancer.
Methods: The aim of this review is to ascertain the sensitivity, specificity, positive and negative predictive value of DRE
for the detection of prostate cancer in symptomatic patients in primary care.
CENTRAL, MEDLINE, EMBASE and CINAHL databases were searched in august 2015 for studies in which a DRE was
performed in primary care on symptomatic patients and compared against a reference diagnostic procedure.
Results: Four studies were included with a total of 3225 patients. The sensitivity and specificity for DRE as a predictor
of prostate cancer in symptomatic patients was 28.6 and 90.7%, respectively. The positive and negative predictive
values were 42.3 and 84.2%, respectively.
Conclusion: This review found that DRE performed in general practice is accurate, and supports the UK NICE
guidelines that patients with a malignant prostate on examination are referred urgently for suspected prostate cancer.
Abnormal DRE carried a 42.3% chance of malignancy, above the 3% risk threshold which NICE guidance suggests
warrants an urgent referral. However this review questions the benefit of performing a DRE in primary care in the first
instance, suggesting that a patient’s risk of prostate cancer based on symptoms alone would warrant urgent referral
even if the DRE feels normal.
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Background
Prostate cancer is the most common cancer amongst
men with 41,736 cases diagnosed in the UK in 2011.
Over the last 35 years, the incidence of prostate cancer
has more than tripled, though much of this increase is
likely to be due to the increasing use of prostate specific
antigen (PSA) blood tests. The mortality rate from pros-
tate cancer in the UK is falling after reaching a peak in
the 1990s, but in 2012, over 10,000 men died of prostate
cancer. Survival from prostate cancer is relatively good
with a five-year survival rate of 85% [1].
There has been considerable debate about the benefits
and harms of early diagnosis of prostate cancer, with
much of the discussion focused around the use of PSA.
Evidence suggests survival is closely related to stage at
diagnosis, with 100% five year survival in patients diag-
nosed with the earliest stage disease compared to less
than 33% five year survival if diagnosed at the latest
stage [1]. This suggests that early diagnosis of prostate
cancer is important. Certainly once a patient is symp-
tomatic, there seems to be little benefit in delaying the
diagnosis.
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Asymptomatic screening using PSA is undertaken, and
accepted in some countries, including the US, however
the U.S. Preventative Services Task Force recommend a
discussion on the potential benefits and harms of PSA
screening, stating that screening offers a “small potential
benefit of reducing the chance of dying of prostate
cancer” but also highlighting that “many men will ex-
perience potential harms of screening” [2]. In the UK,
screening is not recommended routinely, instead Public
Health England runs a ‘prostate cancer risk management
program’ in which patients who are concerned about
prostate cancer are able to have a PSA test after a dis-
cussion with a GP on the benefits and harms of the test
in order to make an informed choice [3]. As a result
most prostate cancers in the UK are identified when pa-
tients present to general practice with a symptom suspi-
cious of prostate cancer such as nocturia or urinary
frequency. It is also worth noting however that there is a
diagnostic challenge as both urinary tract infections and
benign prostatic hypertrophy often present in similar
ways and are much more common diagnoses [4, 5].
The National Institute for Health and Care Excellence
(NICE) has recently updated the guidance on recogni-
tion and referral of suspected cancer in the UK [6]. The
latest NICE guidelines give recommendations on the
recognition and referral of prostate cancer. These guide-
lines state patients should be referred urgently if the
prostate feels malignant on digital rectal examination
and recommends performing digital rectal examination
(DRE) on patients presenting with any lower urinary
tract symptoms including nocturia, urinary frequency,
hesitancy, urgency or retention [6]. A recommendation
supported by Walsh et al. who reviewed DREs under-
taken in primary care and urology clinics for the diagno-
sis of prostate cancer and concluded that DRE is a key
part of the assessment [7]. However, the evidence base
for DRE in symptomatic patients is poor, with NICE
guidelines documenting only one case control study by
Hamilton et al. [4]. As a result it is not known if DRE
performed in primary care is an accurate method of
detecting prostate cancer, or what the risk of prostate
cancer is, if the general practitioner deems the prostate
to be malignant on examination.
Methods
The aim of this review was to evaluate the effectiveness
of DRE performed by general practitioners as a predictor
of prostate cancer in symptomatic patients in a primary
care setting according to the latest NICE guideline
recommendations.
The reporting of this systematic review follows the
recommendations of the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) state-
ment [8]. A protocol was developed and registered in
the PROSPERO register of systematic reviews (registra-
tion number PROSPERO 2015:CRD42015025764) [9].
Search strategy
A search was undertaken for empirical research using
MEDLINE, CINAHL, EMBASE and the Cochrane
Register of Controlled Trials (CENTRAL). Each database
was searched from commencement to August 2015.
Grey literature was searched using the OpenGrey data-
base. Citations of all potentially relevant reviews and
research papers were hand searched. No date or lan-
guage restrictions were applied to the database searches.
The following terms were used in the search all data-
bases: prostate cancer, DRE, primary care. The search
strategy and protocol and be accessed here http://
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=
CRD42015025764. Two reviewers (CF and AD) inde-
pendently screened the title and abstract of all articles
identified by the search to determine eligibility. Full texts
were obtained for all potentially relevant articles and
these were independently assessed by two authors (CF
and AD) to determine eligibility. Final inclusion was
determined by agreement between both reviewers. If no
consensus was reached, a third study author (DJ) was
consulted.
Eligibility criteria
We searched for studies that evaluated the use of DRE
in primary care for the detection of prostate cancer. To
be included in the review studies had to meet three in-
clusion criteria: studies should be randomized controlled
trials, case control or cohort studies; they needed to in-
clude symptomatic patients with any of the symptoms
listed in the NICE guidelines for referral of prostate
cancer; and they studies needed to be conducted in pri-
mary care setting. Studies undertaken in secondary care
or screening studies of asymptomatic patients were ex-
cluded. As this was a review of a diagnostic procedure
the studies should compare DRE to a reference test. The
reference for this review was histological diagnosis of
prostate cancer. The NICE guidelines do not define an
abnormal DRE so definitions from all included studies
were considered.
Outcomes
The primary outcomes were the sensitivity, specificity,
positive (PPV) and negative predictive value (NPV) of
DRE in primary care for the detection of prostate cancer
in symptomatic patients. This was calculated using the
Meta-DiSc software [10]. Secondary outcomes were
cost-effectiveness and adverse effects as a result of the
intervention. Heterogeneity is almost always presumed
in diagnostic test accuracy systematic reviews, and
hence, a random-effects model was used [11].
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Data extraction
Two reviewers (CF and AD) independently extracted
data from included articles using a pre-defined data ex-
traction form. Disagreements were resolved by discus-
sion between the two reviewers with a third reviewer
(DJ) consulted if necessary. Data were extracted on study
participants including age, ethnicity, setting and symp-
toms, the studies inclusion and exclusion criteria, the in-
formation on the DRE and gold standard test of the
study and study outcomes.
Quality assessment
The Newcastle Ottawa quality assessment scale [12] was
used to evaluate the quality of included studies. This
scale is recommended by the Cochrane Handbook for
assessing methodological quality of non-randomised
studies and was chosen as it was highlighted as a simple
tool to apply using eight assessment domains [13].
Hamilton [4] was a case control study and was deter-
mined to be of high methodological quality. The study
adequately defined a case, stating they were identified
from the cancer registry at the Royal Devon and Exeter
Hospital and controls were selected from the community
with no history of disease. The study adequately con-
trolled for age and location. Exposure for both cases and
controls was ascertained from the GP and hospital re-
cords. All cases and controls were included in the final
results with no drop outs.
Three cohort studies [14–16] were included and were
judged to be of high methodological quality. All were
representative of the average age of men with prostate
cancer in the community. Ascertainment of exposure for
all studies was determined from a secure patient medical
record. Participants with a history of prostate cancer
were excluded in all studies. All studies controlled for
symptomatic patients, location and performance of DRE.
However, it should be noted that none of the cohort
studies included documentation of how biopsy was
taken and whether the individual performing the biopsy
was blinded of symptoms and DRE findings.
Results
Study characteristics
Four studies met the inclusion criteria and were in-
cluded in the review (see Fig. 1). The characteristics of
the included studies are shown in Table 1. Three of the
studies were cohort studies [14–16] and one was a case
control study [4]. Two of the studies were conducted in
the US [14, 15], one was conducted in the UK [4] and
one in Spain [16]. A total of 3225 patients were included
in the four papers. The largest study had 1297 partici-
pants [4] and the smallest had just 82 [16]. The age of
participants in included studies ranged from 40 to 89.
All studies documented the symptoms suffered by
patients with the exception of Issa [14] who used the
international prostate symptom score (IPSS). All four
papers included patients with at least one of symptoms
listed in the NICE cancer guidelines, however these were
different in each paper. Three of the studies explicitly
defined an ‘abnormal DRE’ with the exception of
Gelabert Mas [16]. The three papers used very similar
definitions of an abnormal prostate. Hamilton et al. state
that “hard, craggy or nodular glands were classified as
malignant” [4], Issa et al. state that “DRE findings were
classified as abnormal in the presence of prostate indur-
ation and/or nodularity” [14] and Mettlin et al. state that
“a suspicious DRE outcome is defined by the presence of
significant induration, nodularity or asymmetry” [15].
Diagnostic accuracy of DRE
There were 3225 participants included from 4 different
studies. For each of the included studies we were able to
calculate a 2 × 2 table for reference test (biopsy / diagno-
sis of prostate cancer) results versus the diagnostic test
(DRE). This data was then combined to give an overall
sensitivity, specificity, PPV and NPV. This was calculated
using Meta-Disc software. Overall, the pooled sensitivity
and specificity for DRE as a predictor of prostate cancer
in symptomatic patients was found to be 28.6% (95% CI
25.1–32.3%) and 90.7% (95% CI 89.5–91.8%), respect-
ively. These results are shown in Fig. 2. The pooled PPV
and NPV were found to be 42.3 and 84.2%, respectively.
There was no relevant data extractable regarding sec-
ondary outcomes of adverse events or cost effectiveness.
As three out of the four studies were cohort
studies, we performed a sub-analysis of the cohort
studies alone. This produced a sensitivity of 42.7%
(95% CI 37.8–47.7%), a specificity of 86.7% (95% CI
84.9–88.4%), a PPV of 46.1% and a NPV of 85.1%.
Showing that excluding the case control study did not
significantly affect the results.
Discussion
To the authors´ knowledge, this is the first review to
evaluate the specificity, sensitivity, positive and negative
predictive value of DRE as a predictor of prostate cancer
in symptomatic patients in a primary care setting.
With the release of the new cancer referral guidelines
in the UK the threshold of risk for referral for possible
cancer was reduced from 5 to 3%. This suggests that all
patients with signs and symptoms which carry a risk of
cancer greater than 3% should be referred urgently to
secondary care. This review found the pooled positive
predictive value of DRE to detect prostate cancer was
42.3%. This suggests that if a patient with symptoms sug-
gestive of prostate cancer presents to primary care and
has an abnormal feeling prostate examination, then that
patients risk of cancer is 42.3%. This clearly warrants an
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urgent referral for suspected cancer and supports the UK
NICE guidelines.
However, the pooled sensitivity in this review was low,
28.6% suggesting that many patients diagnosed with
prostate cancer do not have an abnormal DRE. In
addition to the low sensitivity, the pooled negative pre-
dictive value was 84.2%, this suggests that symptomatic
patients who present to primary care and have a normal
prostate examination still have a risk of cancer of 15.8%,
which above the 3% risk threshold suggested by NICE.
These findings show that patients in these included
studies should be urgently referred for suspected pros-
tate cancer regardless of the DRE result. This suggests
that DRE performed in primary care is an unnecessary
investigation, adding little to the decision to refer, which
should be made on the basis of symptoms alone. In
addition to this, it is possible that DRE may delay the
patient in seeking help with some qualitative research
finding that the prospect of a DRE may deter some men
from seeking medical help for symptoms suggestive of
prostate cancer and prostate cancer screening [17–19].
This qualitative research suggests that performing DRE
in primary may in fact be delaying the diagnosis of
prostate cancer.
The UK NICE guidelines make their recommendations
to refer patients with a prostate deemed malignant on
Table 1 Characteristics of included studies
Study ID Country Evidence
level
Methods Number of
participants
Age range
(years)
Index test Reference Outcomes
Mettlin 1991 USA 2b Prospective
cohort study
1218 55–70 PSA, DRE and TRUS Biopsy Sensitivity, specificity and
PPV of DRE, PSA and TRUS.
Gelabert Mas 1997 Spain 2b Prospective
cohort study
82 > 50 PSA/DRE Biopsy Sensitivity, specificity, and
PPV of DRE and PSA.
Hamilton 2006 UK 4 Case control 1297 ≥ 40 PSA/DRE Diagnosis of
prostate cancer
PPV of symptoms, DRE
and PSA.
Issa 2006 USA 2b Retrospective
cohort study
628 40–89 PSA/DRE Biopsy Sensitivity, specificity, PPV
and NPV of DRE and PSA.
Fig. 1 PRISMA Diagram
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examination on the evidence from just one study. This
systematic review includes four studies which consider
the effectiveness of DRE for diagnosing prostate cancer
in symptomatic patients in primary care and thus
provides stronger evidence for performing DRE in these
patients. However, the majority of the available literature
concentrates on using DRE as a screening test in unse-
lected asymptomatic patients. More research on the
effectiveness of DRE in primary care would help to pro-
vide further evidence for the NICE guidelines and ensure
that DRE is a useful investigation when performed by
GPs.
Whilst the included studies were judged to be of high
methodological quality it is difficult to draw conclusions
based on a small number of studies, all of which were
published over ten years ago, are of low impact and are
largely heterogeneous. In addition, there are limitations
of including case control studies in reviews of diagnostic
test accuracy as they tend to overestimate diagnostic
accuracy. In addition to this Hamilton et al. included pa-
tients diagnosed with prostate cancer by a urologist
without having a biopsy which means not all participants
in the study received the same index test. Whilst this
clinically makes sense and is common in studies in
which the reference test is invasive, it is nonetheless a
limitation of the study. These limitations were investi-
gated using a sensitivity analysis which excluded the
Hamilton et al. study, it was found that excluding the
case control study did not significantly affect the results.
To be included in this review the papers had to
include patients with at least one of the symptoms sug-
gested by NICE. However, in each paper the combin-
ation of symptoms in the patients was different and in
some was poorly defined.
Due to the nature of using secondary data, there were
some papers in which full information was not available.
It was agreed in each study the DRE had been performed
in primary care, however it was often not clear who had
performed the examination. In addition to this, only
three of the four studies adequately defined an abnormal
DRE, the forth study did not provide a definition of
abnormal or positive DRE.
One of the papers (Issa 2006) caused some difficulty in
analysis due to a possible typing error. In the text of the
study they state symptoms were classified as mild mod-
erate or severe using IPSS with mild symptoms classified
between 1 and 7, however in the results they present
mild symptoms as 0–7, this could mean patients with an
IPSS score of 0, who may be asymptomatic were
included in the results. Clarification was sought from
the authors however no response was received.
The vast majority of existing literature focuses on the
use of DRE as a screening tool. A Cochrane review on
screening for prostate cancer included five studies and
found that screening did not significantly decrease pros-
tate cancer-specific mortality [20]. This review supports
the recommendations of NICE which suggests that GPs
refer patients urgently on the basis of an abnormal DRE.
The NICE recommendation was made on the basis of
the Hamilton 2006 paper which is included in this
review. There is also qualitative literature to suggest that
the prospect of a DRE may deter men from presenting
to primary care.
Conclusion
The most recent UK NICE guidelines recommend that
general practitioners undertake a digital rectal examin-
ation on all patients with lower urinary tract symptoms.
Fig. 2 Pooled sensitivity and specificity for DRE as a predictor of prostate cancer in symptomatic patients
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The guidelines suggest referring patients under the two
week wait referral pathway if the prostate feels malig-
nant. This is the first review to look at the accuracy of
digital rectal examination by general practitioners for
the diagnosis of prostate cancer in symptomatic patients.
We found only four studies on the effectiveness of DRE
for the diagnosis of prostate cancer in symptomatic pa-
tients in primary care, with much of the available litera-
ture focusing on screening. DRE is widely used and
recommended for the assessment of patients in primary
care. It is a simple, safe and cost-effective diagnostic
tool, The findings of the review support the NICE guide-
lines and recommend urgent referral for suspected can-
cer in patients with an abnormal DRE, however the
review casts doubt on the use of DRE as a diagnostic
tool in primary care due to the low sensitivity and nega-
tive predictive value. More research is needed to assess
its effectiveness in diagnosing prostate cancer in symp-
tomatic patients.
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